54 Participants Needed

ALN-HTT02 for Huntington's Disease

Recruiting at 11 trial locations
AC
Overseen ByAlnylam Clinical Trial Information Line
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Alnylam Pharmaceuticals

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment ALN-HTT02 for Huntington's Disease?

Research shows that reducing the levels of the huntingtin protein, which ALN-HTT02 aims to do, has been beneficial in animal models of Huntington's Disease, improving motor and cognitive symptoms. Similar treatments that lower huntingtin protein levels have shown promise in early human trials, suggesting potential benefits for ALN-HTT02.12345

Is ALN-HTT02 safe for humans?

In a study of a similar treatment, RG6042, which also reduces huntingtin protein levels, it was found to be generally safe and well tolerated in humans over a 4-month period. Additionally, reducing huntingtin protein in animal studies was generally safe and well tolerated.15678

How is the drug ALN-HTT02 different from other treatments for Huntington's Disease?

ALN-HTT02 is unique because it targets the underlying cause of Huntington's Disease by reducing the levels of the mutant huntingtin protein, which is responsible for the disease's progression. This approach is different from other treatments that mainly address symptoms rather than the root cause.145910

What is the purpose of this trial?

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.

Research Team

MD

Medical Director

Principal Investigator

Alnylam Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

My condition is in stage 2 or early stage 3 of Huntington's disease.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Double-blind Treatment

Participants receive a single dose of either ALN-HTT02 or placebo

Single dose administration

Open-label Treatment

Participants have the option to receive a single dose of ALN-HTT02

Single dose administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 12 months

Treatment Details

Interventions

  • ALN-HTT02
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ALN-HTT02Experimental Treatment1 Intervention
Participants will be administered a single dose of ALN-HTT02 during the Double-blind Part of the study. Participants who received ALN-HTT02 in the Double-blind part of the study will not receive an additional dose during the Open-label part of the study
Group II: Placebo + ALN-HTT02Placebo Group2 Interventions
Participants will be administered a single dose of placebo during the Double-blind Part of the study. Participants will have the option to receive a single dose of ALN-HTT02 during the Open-Label Part of the study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alnylam Pharmaceuticals

Lead Sponsor

Trials
81
Recruited
16,100+

Dr. Yvonne Greenstreet

Alnylam Pharmaceuticals

Chief Executive Officer since 2021

MD from the University of Leeds, MBA from INSEAD

Dr. Pushkal Garg

Alnylam Pharmaceuticals

Chief Medical Officer since 2016

MD from Columbia University

Findings from Research

A recent phase 1/2a study involving 46 adults with early Huntington disease showed that the antisense oligonucleotide RG6042, which partially reduces huntingtin protein levels, was generally safe and well tolerated over four monthly doses.
Evidence from both human case studies and mouse models suggests that reducing variant huntingtin protein can improve symptoms and may not pose significant risks, indicating a positive risk-benefit profile for therapies targeting huntingtin levels in Huntington disease.
Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.Leavitt, BR., Kordasiewicz, HB., Schobel, SA.[2021]
A 36-year-old woman with the akinetic-rigid variant of Huntington's disease showed significant improvement in parkinsonism, bradykinesia, and dystonia after 5 days of intravenous amantadine treatment, as measured by the Unified Huntington's Disease Rating Scale.
This case suggests that amantadine, which increases dopamine levels in the brain, may be beneficial for patients with this specific variant of Huntington's disease, marking a novel application of the drug beyond its typical use in Parkinson's disease.
Amantadine in the akinetic-rigid variant of Huntington's disease.Magnet, MK., Bonelli, RM., Kapfhammer, HP.[2013]
CERE-120 (AAV2-NTN) therapy showed significant protective effects in a mouse model of Huntington's disease, improving motor function and reducing symptoms like clasping behavior.
The treatment also provided neuroprotection by preserving neurons in both the striatum and prefrontal cortex, suggesting that gene delivery of neurturin could be a promising approach for treating Huntington's disease.
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.Ramaswamy, S., McBride, JL., Han, I., et al.[2019]

References

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. [2021]
Emerging therapies in Huntington's disease. [2020]
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. [2022]
Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials. [2021]
Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks. [2021]
Amantadine in the akinetic-rigid variant of Huntington's disease. [2013]
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. [2019]
In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease. [2017]
Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion. [2016]
10.United Statespubmed.ncbi.nlm.nih.gov
Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity